Biotech Enablement Post-Ariad: Written Description and Scope of Genus Claims

TL;DR
After Ariad v. Eli Lilly, US written description doctrine requires that the specification demonstrate that the inventor was in possession of the full scope of a genus claim at the time of filing. For biotech inventions, this typically requires either a representative number of species or disclosure of structural features that correlate with the claimed function. Enablement under the Wands factors remains a separate but related requirement. See our MPEP written description support guide by the PatentPaper research team for USPTO examination practice and our CRISPR gene editing patents guide by the PatentPaper research team for thicket and enablement issues in gene editing.

The Ariad Standard: Possession and Blaze Marks

The en banc Federal Circuit in Ariad held that the written description requirement is separate from enablement and demands that the specification show that the inventor was in possession of the claimed invention. For genus claims, the specification must either describe a representative number of species or disclose structural features that correlate with the claimed function across the genus. "Blaze marks" in the specification that guide the skilled artisan to the claimed species are often required.

Example: In a 2023 Federal Circuit decision involving antibodies, the court affirmed invalidity for lack of written description because the specification disclosed only a single antibody with the claimed binding properties and did not describe a representative number of species or common structural features that would allow a skilled artisan to predict which other antibodies would have the same function.

Representative Species vs Structural Correlation

Written description can be satisfied by disclosing a representative number of species that fall within the claim and that are sufficient to demonstrate possession of the genus. Alternatively, the specification can disclose structural features (for example, a consensus sequence or a set of conserved residues) that correlate with the claimed function across the genus. The more unpredictable the art, the more species or structural detail is required.

Enablement and the Wands Factors in Unpredictable Arts

Enablement requires that the specification teach a person of ordinary skill how to make and use the invention without undue experimentation. In biotech, the Wands factors (breadth of claims, nature of the invention, state of the prior art, level of predictability, amount of direction, presence of working examples, quantity of experimentation needed) are applied rigorously. A specification that is enabling for a narrow species may not be enabling for a broad genus.

PTAB and District Court Application Post-Ariad

Both the PTAB and district courts apply Ariad and its progeny to invalidate broad genus claims in biotech and antibody cases. The trend has been toward requiring more concrete disclosure of representative species or structural correlation, and away from allowing functional genus claims supported only by a few examples and a "make and screen" disclosure.

Strategic Claim Drafting and Prosecution to Maximize Scope and Validity

Applicants should draft claims at multiple levels of generality, include working examples that demonstrate the correlation between structure and function, and consider filing continuations to pursue narrower, better-supported claims if broader claims are rejected or invalidated. Prosecution should focus on identifying the structural features or representative species that support the claimed genus.

FAQ

What is the difference between written description and enablement after Ariad?

Written description asks whether the inventor possessed the claimed invention at filing (did the specification show the inventor had invented the full scope?). Enablement asks whether the specification teaches a skilled person how to make and use the invention without undue experimentation. Both must be satisfied.

How many representative species are enough for a biotech genus claim?

There is no fixed number. The Federal Circuit has upheld claims supported by a few species when the art is relatively predictable and the specification discloses a clear structural correlation. In unpredictable arts or for very broad genera, more species or detailed structural disclosure is required.

Can I use "make and screen" language to support a broad genus claim?

Generally no, post-Ariad. A disclosure that the skilled artisan can "make and screen" variants for the desired function is usually insufficient to show possession of the full genus or to enable it without undue experimentation.

Does Ariad apply to all types of biotech claims?

The written description doctrine applies to all claims, but it is most stringent for genus claims in unpredictable arts (antibodies, small molecules, nucleic acids, proteins). Narrow species claims or claims with strong structural support are less vulnerable.

How does the PTAB apply Ariad in IPRs and PGRs?

The PTAB applies the same Federal Circuit precedent. Broad genus claims in biotech patents are frequently invalidated in post-grant proceedings for lack of written description or enablement when the specification provides only a few examples and functional language.

Can I fix a written description problem by amending the claims?

Yes, by narrowing to a supported subgenus or species, provided the amendment does not introduce new matter. Support must be found in the original specification.

Which PatentPaper resources cover written description and enablement in biotech prosecution?

Our MPEP written description support and CRISPR gene editing patents articles by the PatentPaper research team provide detailed analysis and prosecution strategies for enablement and written description issues in biotech.